Department of Urology, Tianjin First Central Hospital, Tianjin, China.
Int Braz J Urol. 2024 Nov-Dec;50(6):683-702. doi: 10.1590/S1677-5538.IBJU.2024.0191.
To evaluate the safety and effectiveness of robot-assisted radical cystectomy (RARC), laparoscopic radical cystectomy (LRC), and open radical cystectomy (ORC) in bladder cancer.
A literature search for network meta-analysis was conducted using international databases up to February 29, 2024. Outcomes of interest included baseline characteristics, perioperative outcomes and oncological outcomes.
Forty articles were finally selected for inclusion in the network meta-analysis. Both LRC and RARC were associated with longer operative time, smaller amount of estimated blood loss, lower transfusion rate, shorter time to regular diet, fewer incidences of complications, and fewer positive surgical margin compared to ORC. LRC had a shorter time to flatus than ORC, while no difference between RARC and ORC was observed. Considering lymph node yield, there were no differences among LRC, RARC and ORC. In addition, there were statistically significant lower transfusion rates (OR=-0.15, 95% CI=-0.47 to 0.17), fewer overall complication rates (OR=-0.39, 95% CI=-0.79 to 0.00), fewer minor complication rates (OR=-0.23, 95% CI=-0.48 to 0.02), fewer major complication rates (OR=-0.23, 95% CI=-0.68 to 0.21), fewer positive surgical margin rates (OR=0.22, 95% CI=-0.27 to 0.68) in RARC group compared with LRC group.
LRC and RARC could be considered as a feasible and safe alternative to ORC for bladder cancer. Notably, compared with LRC, RARC may benefit from significantly lower transfusion rates, fewer complications and lower positive surgical margin rates. These data thus showed that RARC might improve the management of patients with muscle invasive or high-risk non-muscle invasive bladder cancer.
评估机器人辅助根治性膀胱切除术(RARC)、腹腔镜根治性膀胱切除术(LRC)和开放性根治性膀胱切除术(ORC)治疗膀胱癌的安全性和有效性。
截至 2024 年 2 月 29 日,我们对国际数据库进行了网络荟萃分析的文献检索。感兴趣的结局包括基线特征、围手术期结局和肿瘤学结局。
最终有 40 篇文章被纳入网络荟萃分析。与 ORC 相比,LRC 和 RARC 的手术时间更长、估计失血量更少、输血率更低、恢复正常饮食时间更短、并发症发生率更低、切缘阳性率更低。与 ORC 相比,LRC 的肛门排气时间更短,而 RARC 与 ORC 之间无差异。考虑到淋巴结产量,LRC、RARC 和 ORC 之间没有差异。此外,RARC 组的输血率(OR=-0.15,95%CI=-0.47 至 0.17)、总并发症发生率(OR=-0.39,95%CI=-0.79 至 0.00)、轻微并发症发生率(OR=-0.23,95%CI=-0.48 至 0.02)、主要并发症发生率(OR=-0.23,95%CI=-0.68 至 0.21)、切缘阳性率(OR=0.22,95%CI=-0.27 至 0.68)均显著低于 LRC 组。
LRC 和 RARC 可被视为膀胱癌的一种可行且安全的 ORC 替代方案。值得注意的是,与 LRC 相比,RARC 可能受益于显著更低的输血率、更少的并发症和更低的切缘阳性率。这些数据表明,RARC 可能改善肌层浸润性或高危非肌层浸润性膀胱癌患者的治疗管理。